What is emphysema, and how does it differ from COPD?
Emphysema is a lung disease characterized by the irreversible destruction of the alveolar walls—the small sacs where gas exchange between the air and the blood takes place. The destruction of the interalveolar septa creates large air spaces that trap air and reduce the surface area available for gas exchange (normally 70 m² in adults). Emphysema is a component of COPD (chronic obstructive pulmonary disease)—often associated with chronic bronchitis. Specialized medical care is essential—the natural products available in the respiratory health line provide complementary support.
- Mechanism of alveolar destruction: Tobacco activates alveolar macrophages, which release proteases (elastases, metalloproteinases) that break down the elastic fibers of the alveolar wall—this destruction is accelerated in individuals with alpha-1 antitrypsin deficiency (A1AT—a liver protein that normally inhibits these proteases)—the loss of elasticity leads to distension and trapping of air at the end of exhalation (hyperinflation)
- Progressive symptoms: exertional dyspnea (first sign—shortness of breath when climbing stairs or walking briskly)—progressing to dyspnea at rest—chronic cough with or without mucus—prolonged and labored exhalation— "barrel chest" (rounded, hyperresonant chest) — cyanosis of the lips and fingers in advanced stages — clubbing
- Emphysema and COPD: COPD encompasses emphysema (parenchymal destruction) and chronic bronchitis (hypersecretion and bronchial obstruction) — most COPD patients have both components — defined by an FEV1/FVC ratio < 0.70 after bronchodilation (GOLD criteria) — GOLD classification 1 through 4 based on the severity of obstruction
- Alpha-1 antitrypsin (A1AT): hereditary deficiency (ZZ allele—1 in 2,000 to 1 in 5,000) — early pan-lobular emphysema (< 45 years of age), predominantly in the basal regions, even among nonsmokers — an A1AT test should be performed in all patients with emphysema < 50 years of age or without significant smoking history
Diagnosis, Treatments, and Pulmonary Rehabilitation
The diagnosis of emphysema is based on spirometry (measurement of lung volumes and flow rates)—FEV₁ is the key indicator of severity—and on high-resolution chest CT (HRCT), which directly visualizes alveolar destruction. Smoking cessation is the only measure that significantly slows progression—all other interventions improve symptoms and quality of life without halting the destruction.Bronchial obstruction and associated bronchial secretions are managed concurrently.
- Bronchodilators — maintenance therapy: long-acting beta-2 agonists (formoterol, salmeterol, indacaterol) — long-acting anticholinergics (tiotropium, umeclidinium — the most effective in COPD) — LABA+LAMA combinations — reduce dyspnea, improve exercise tolerance, and decrease exacerbations — associated bronchospasm responds to rapid-acting beta-2 agonists (salbutamol)
- Pulmonary rehabilitation: supervised multidisciplinary program (respiratory physical therapy, exercise training, therapeutic education, psychological support) — reduces dyspnea, improves exercise tolerance and quality of life — efficacy comparable to any drug therapy in moderate to severe stages — recommended by the HAS for all symptomatic COPD patients (GOLD 2 to 4)
- Long-term oxygen therapy (LTOT): indicated if PaO₂ < 55 mmHg at rest (severe hypoxemia) — at least 15 hours/day — improves survival in severe hypoxemic COPD — not indicated without documented hypoxemia — respiratory comfort aids available in the respiratory aids lineup
- Surgical and endoscopic procedures: lung volume reduction surgery (LVRS) — endobronchial valves (endoscopic obstruction of emphysematous segments — less invasive) — lung transplantation (for very advanced cases in selected patients)
Daily life, diet, and prevention of emphysema
Emphysema profoundly alters daily life—dyspnea limits activities, causes anticipatory anxiety, and contributes to social isolation and depression (prevalent in 40% of COPD patients). The panic-dyspnea syndrome is a common complication that can be prevented through relaxation and breathing control techniques. Essential oils for respiratory comfort can provide complementary aromatic support.
- Nutrition and emphysema: malnutrition is common (shortness of breath during meals, increased metabolic rate due to respiratory effort)—maintaining a healthy weight is crucial—eat small, frequent meals; follow a diet rich in protein and antioxidants (vitamin C, zinc)—avoid large meals (gastric distension worsens dyspnea due to diaphragmatic pressure)
- Adapted physical activity: physical deconditioning exacerbates the vicious cycle of dyspnea–inactivity–deconditioning — walking, stationary cycling, swimming at an appropriate intensity and under medical supervision — improves exercise tolerance and reduces the perception of shortness of breath — pursed-lip breathing (2-second nasal inhalation, 4-second exhalation through pursed lips) slows the respiratory rate and reduces hyperinflation
- Prevention: smoking cessation (nicotine replacement therapy, varenicline, psychological counseling)—avoid air pollution and occupational exposure—annual influenza and pneumococcal vaccination (infectious exacerbations are the leading cause of acute deterioration) — spirometry screening for smokers over 40, even if asymptomatic
- Asthma and emphysema: some patients present with a mixed asthma-COPD picture (ACOS—Asthma COPD Overlap Syndrome) — differential diagnosis is important because management differs — inhaled corticosteroids are more effective for the asthma component than for pure emphysema
